Results 81 to 90 of about 4,259,087 (330)

Multi‐Technique Integration Identifies O‐GlcNAc Transferase in Fibroblast‐Like Synoviocytes as a Therapeutic Target for Rheumatoid Arthritis

open access: yesAdvanced Science, EarlyView.
AI‑guided single‑cell transcriptomics identifies OGT as a key regulator enriched in rheumatoid arthritis fibroblast‑like synoviocytes (RA‐FLSs). Inflammatory stimuli activate the OGT–SAP130 axis, which modulates the H3K27ac/H3K27me3 balance and epigenetically silences BTG2, promoting aggressive transformation of RA‑FLSs.
Duoli Xie   +14 more
wiley   +1 more source

Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer

open access: yesEpigenetics, 2020
Histone deacetylases (HDACs) have been linked to a variety of cancers, and HDAC inhibitors (HDACi) are a promising class of drugs that have demonstrated anti-cancer effects.
Yingyan Han   +10 more
doaj   +1 more source

Targeting radiation‐induced upstream stimulatory factor‐1 by histone deacetylase inhibitors to reverse radioresistance in prostate cancer

open access: yesCancer Reports, 2022
Background Ionizing radiation (IR) is a standard modality for the management of solid tumors. Apart from its killing effects, IR can induce pro‐survival factors leading to radioresistance of cancer.
Seema Gupta, Mansoor M. Ahmed
doaj   +1 more source

HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis

open access: yesTherapeutic Advances in Chronic Disease, 2019
Fibrosis usually results from dysregulated wound repair and is characterized by excessive scar tissue. It is a complex process with unclear mechanisms.
X. Lyu   +4 more
semanticscholar   +1 more source

Development Of Elisa-Based Hdac Activity Assay For Identification Of Isoform Selective Hdac Inhibitors [PDF]

open access: yes, 2014
Cancers are one of the leading causes of death in United States, effecting roughly 20% of the population. To develop effective anti-cancer agents, vast research is in progress that targets various factors leading to cancer.
Padige, Geetha
core   +1 more source

Presentation1_DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitors in vitro.pdf

open access: yes, 2022
Cutaneous T-cell lymphomas (CTCLs) are a subset of T-cell malignancies presenting in the skin. The treatment options for CTCL, in particular in advanced stages, are limited.
Muddassir Malik (14072394)   +7 more
core   +1 more source

AARS1‐Mediated H3K27 Lactylation Rewires Glycolysis to Sustain Aggressive and Recurrent Bladder Cancer

open access: yesAdvanced Science, EarlyView.
AARS1 drives PI3K–AKT–mTOR‐dependent glycolysis in bladder cancer, promoting lactate accumulation, increased lactylation, H3K27la enrichment at the HK2 promoter, and HK2 transcription. HK2 reinforces glycolysis, sustaining a metabolic–epigenetic program associated with tumor progression, recurrence, and metastasis.
Qin Yuan   +13 more
wiley   +1 more source

Structures of representative HDAC and topoisomerase I inhibitors.

open access: yes, 2018
Structures of representative HDAC and topoisomerase I inhibitors.
Raffaella Cincinelli (192154)   +12 more
core   +1 more source

Targeting the KAT7/H3K14ac/RAC2 Axis Mediates OXPHOS to Promote Stemness Maintenance and Malignancy in Glioblastoma

open access: yesAdvanced Science, EarlyView.
SOX2 upregulates KAT7 in glioma stem cells, where KAT7 deposits H3K14 acetylation at the RAC2 promoter to activate RAC2 transcription. RAC2‐GTP subsequently promotes PAK1/2/3 phosphorylation, increasing tricarboxylic acid cycle flux and mitochondrial respiration to support glioblastoma malignancy.
Jilong Liu   +13 more
wiley   +1 more source

From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs

open access: yesEMBO Molecular Medicine, 2019
Reversing or slowing the aging process brings great promise to treat or prevent age‐related disease, and targeting the hallmarks of aging is a strategy to achieve this.
Rebecca L. McIntyre   +4 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy